| Literature DB >> 19936223 |
Abstract
Entities:
Mesh:
Year: 2009 PMID: 19936223 PMCID: PMC2777391 DOI: 10.1371/journal.pmed.1000141
Source DB: PubMed Journal: PLoS Med ISSN: 1549-1277 Impact factor: 11.069
Examples of the types of systematic reviews needed in different steps in the policymaking process.
| Steps in a Policymaking Process | Sub-Steps that Involve Acquiring Data and/or Research Evidence | Examples of the Types of Systematic Reviews That Can Be Acquired |
|
| Identifying indicators to establish the magnitude of the problem (or the factors that contribute to it) | Reviews of observational studies (e.g., administrative database studies, community surveys) |
| Making comparisons (over time, across settings or against plans) to establish the magnitude of the problem (or the factors that contribute to it) | Reviews of observational studies (e.g., administrative database studies, community surveys) | |
| Highlighting alternative framings of the problem to assist with mobilizing support among different groups to address the problem | Reviews of qualitative studies that examine stakeholders' views about and experiences with the problem (e.g., studies in which narrative data are collected from individual or groups of “informants” through interviews, focus groups, participant observation, or from documents) | |
|
| Identifying policy and program options that could affect the problem (or the factors that contribute to it) | (Frameworks embedded in) Reviews or overviews of systematic reviews of any type if frameworks were used to organise the search for, and presentation of, research evidence (as well as theories and frameworks that are the focus of articles/reports in their own right) |
| Characterizing the positive effects (benefits) of each policy option | Reviews of effectiveness studies (e.g., randomized controlled trials, interrupted time series) | |
| Characterizing the negative effects (harms) of each policy option | Reviews of effectiveness and/or observational studies | |
| Characterizing the cost-effectiveness of policy options | Reviews of economic evaluations | |
| Identifying the key elements of complex policy options (to facilitate local adaptation if necessary) | Reviews of qualitative studies that examine how or why interventions work and/or reviews of observational studies | |
| Characterizing stakeholders' views about and experiences with the policy options | Reviews of qualitative studies that examine stakeholders' views about and experiences with particular options | |
|
| Identifying potential barriers to implementation at the level of patients/consumers, health workers, organizations, and systems | Reviews of observational studies and/or reviews of qualitative studies |
| Characterizing the effects of appropriately targeted implementation strategies | Reviews of effectiveness studies |
Examples of review-derived products targeted at policymakers and stakeholders.
| Type | Goal | Examples | |
| Sponsor/Initiative | Systematic Reviews Included | ||
|
|
| ACC Policy Liaison Initiative | Reviews of policy-relevant reviews, which are typically health system interventions, provider behaviour-change interventions, and consumer-targeted reviews |
| DARE | Reviews of the effects of health or health-system interventions | ||
| Effective Health Care Research Programme Consortium | Same as ACC but with a particular focus on LMICs | ||
| Evidence Aid | Same as DARE but with a particular focus on natural disasters and other health care emergencies (originally done in response to the 2004 tsunami and now updated in response to the H1N1 pandemic) | ||
| Health Knowledge Network of the CC&CRG Evidence Bulletins | Reviews of the effects of consumer-targeted reviews | ||
| Health-evidence.ca | Reviews of the effects of public-health interventions | ||
| Reproductive Health Library | Reviews of the effects of reproductive-health interventions, with a particular focus on LMICs | ||
| Rx for Change | Reviews of the effects of prescribing-related interventions (and provider behaviour-change interventions more generally) | ||
| SUPPORT | Same as ACC but with a particular focus on LMICs | ||
|
|
| IDEAHealth | Reviews of the effects of health system financing mechanisms |
| SUPPORT | Reviews of the effects of interventions to support the delivery of cost-effective interventions in health systems and in maternal and child health, with a particular focus on LMICs | ||
| Cochrane Collaboration's EPOC review group | Reviews of the effects of provider behaviour-change interventions | ||
| Cochrane Collaboration's CC&CRG review group | Protocol for a review of the effects of consumer-targeted interventions | ||
|
|
| Health Evidence Network/European Observatory on Health Systems and Policies | Reviews that inform problem definition, policy option characterization, and policy implementation-strategy characterization at the regional level, with a particular focus on the European Region |
| EVIPNet | Reviews that inform problem definition, policy option characterization, and policy implementation-strategy characterization at the country level, with a particular focus on countries in Africa, Asia, and the Americas with formally established evidence-to-policy partnerships (EVIPNet) | ||
ACC, Australasian Cochrane Centre; CC&CRG, Cochrane Consumers and Communication; DARE, Database of Abstracts of Reviews of Effects; EPOC, Effective Practice and Organization of Care; EVIPNet, Evidence-Informed Policy Networks; IDEAHealth, International Dialogue on Evidence-Informed Action to Achieve Health Goals in Developing Countries; LMICs, low- and middle-income countries; SUPPORT, Supporting Policy Relevant Reviews and Trials.
Examples of activities to support the use of systematic reviews and review-derived products by policymakers and stakeholders.
| Approach | Examples of Activities |
| Promoting a climate that supports the use of reviews and review-derived products in policymaking processes | Citing examples from the past or from other jurisdictions where the use of reviews made the difference between policy success and policy failure |
| Conducting an audit of policy documents to identify whether and how existing systematic reviews were cited | |
| Modifying policymaking processes to give an explicit role for systematic reviews, however, this is likely possible only for “routine” decisions like coverage decisions about prescription drugs and other “technologies” | |
| Producing reviews and review-derived products that address high-priority policy issues | Undertaking priority-setting processes that identify short term (1–6 mo) requirements for review-derived products, medium-term (6–18 mo) requirements for systematic reviews, and long-term (>18 mo) requirements for primary research |
| Engaging policymakers and stakeholders in the production of reviews and review-derived products | |
| Engaging policymakers and stakeholders in the “merit review” of reviews and review-derived products | |
| Packaging reviews and review-derived products for policymakers and stakeholders | Wording the title in a way that would engage policymakers and stakeholders (e.g., as a question, with a solution-orientation) |
| Presenting findings using an “inverted pyramid” (e.g., bulleted key messages, executive summary, full report) | |
| Highlighting the take-home messages from the review, particularly decision-relevant information (e.g., benefits and harms of policy options) | |
| Highlighting the contexts in which the included studies were conducted that might influence assessments of local applicability | |
| Highlighting the characteristics of the participants in the included studies and the contexts in which the studies were conducted that might raise equity considerations | |
| Using a format that is consistent, visually interesting (e.g., a mix of colours and of bulleted text, figures, and tables), and “skimmable” | |
| Using language that is appropriate to policymakers and stakeholders, with technical language restricted to an appendix | |
| Disseminating reviews and review-derived products to policymakers and stakeholders | Providing an option to sign up for an e-mail alert when new reviews or review-derived products are posted online |
| Sending a “refresher” e-mail alert about a review or review-derived product when a “window of opportunity” opens | |
| Engaging policymakers and stakeholders in providing online commentaries about specific reviews or review-derived products | |
| Providing online briefings (e.g., webinars) about specific reviews or review-derived products | |
| Providing face-to-face briefings about specific reviews or review-derived products | |
| Giving presentations at meetings about specific reviews or review-derived products coupled with policymaker commentaries | |
| Executing proactive knowledge-translation strategies (e.g., identifying key messages, determining the principal target audiences for each of these messages, seeking out the most credible messenger for these messages and engaging their interest in becoming involved in the communication of these messages, and supporting their communication efforts) | |
| Providing policymakers and stakeholders with the resources, skills, and opportunities to find and use reviews and review-derived products when they need them | Making reviews and review-derived products available through policymaker-targeted, searchable databases |
| Providing policymakers and stakeholders with training so that they can find and use reviews and review-derived products and understand their value relative to other sources of research evidence | |
| Organizing “deliberative dialogues” at which the knowledge arising from systematic reviews can be combined with the tacit (i.e., how to) knowledge and other types of knowledge brought forward by participating policymakers and stakeholders (e.g., about on-the-ground realities and constraints, citizens' values and beliefs, interest group power dynamics, and institutional constraints) |
PPD, Program in Policy Decision-Making; CCNC, Canadian Cochrane Network and Centre.